Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 7Adenocarcinoma of Lung 7Neoplasm Metastasis 4Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Melanoma 2Glioblastoma 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Liver Neoplasms 1Laryngeal Diseases 1Hepatic Impairment 1Gliosarcoma 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Bronchial Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

tazemetostat 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hepatic Impairment × capmatinib × Clear all
NCT02474537 2020-12-10

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Novartis

Phase 1 Completed
31 enrolled

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡